| Iron and infection |
38 |
| Modern iron replacement therapy: clinical and pathophysiological insights |
25 |
| Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study |
19 |
| Chinese guidelines for treatment of adult primary immune thrombocytopenia |
15 |
| Iron overload in myelodysplastic syndromes (MDS) |
14 |
| New insights into the biology of acute myeloid leukemia with mutated NPM1 |
13 |
| Immunopathogenesis and immunotherapy of multiple myeloma |
13 |
| Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies |
12 |
| Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation |
11 |
| A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma |
11 |
| Outcomes in children with hemophagocytic lymphohistiocytosis treated using HLH-2004 protocol in Japan |
11 |
| Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance |
10 |
| Single cord blood transplantation in Japan; expanding the possibilities of CBT |
9 |
| NK cell therapy for hematologic malignancies |
8 |
| Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis |
8 |
| Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system |
8 |
| Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16 |
8 |
| Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation |
7 |
| Targeting transcription factors in acute myeloid leukemia |
7 |
| Current status and progress of lymphoma management in China |
7 |
| Therapeutic doses of doxorubicin induce premature senescence of human mesenchymal stem cells derived from menstrual blood, bone marrow and adipose tissue |
6 |
| Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice |
6 |
| Treatment-free remission in patients with chronic myeloid leukemia |
6 |
| Atypical SIFD with novel TRNT1 mutations: a case study on the pathogenesis of B-cell deficiency |
6 |
| Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study |
6 |
| Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia |
6 |
| Clinical update on hypomethylating agents |
6 |
| Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms |
6 |
| Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives |
6 |
| STAT3 mutations in natural killer cells are associated with cytopenia in patients with chronic lymphoproliferative disorder of natural killer cells |
6 |
| Evaluation of the safety and efficacy of daratumumab outside of clinical trials |
6 |
| VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era |
6 |
| Targeting autophagy in lymphomas: a double-edged sword? |
6 |
| Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies |
6 |
| beta-Thalassemia intermedia: a comprehensive overview and novel approaches |
6 |
| Intestinal thrombotic microangiopathy: a distinct entity in the spectrum of graft-versus-host disease |
5 |
| Hematopoietic stem cell transplantation for acute myeloid leukemia |
5 |
| Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study |
5 |
| Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence |
5 |
| Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells |
5 |
| Study of pathophysiology and molecular characterization of congenital anemia in India using targeted next-generation sequencing approach |
5 |
| Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial |
5 |
| Circulating level of Th17 cells is associated with sensitivity to glucocorticoids in patients with immune thrombocytopenia |
5 |
| Regulation of unfolded protein response in hematopoietic stem cells |
5 |
| The hematopoietic stem cell diet |
5 |
| Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan |
5 |
| JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM) |
5 |
| Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia |
5 |
| Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan |
5 |
| A synonymous splice site mutation in IL2RG gene causes late-onset combined immunodeficiency |
5 |
